CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells. The overall study objectives are to evaluate the safety and efficacy of CordIn™.
Allogeneic Stem Cell Transplantation of CordIn™, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies
CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.
The trial ends when the last patient completes their last visit. The overall study objectives are to evaluate the safety and efficacy of CordIn™: single ex-vivo expanded cord blood unit transplantation in patients with hemoglobinopathies (sickle cell disease or thalassemia major) following a preparative therapy.
Sickle Cell DiseaseThalassemia
You can join if…
Open to people ages 2–25
Patient is a candidate for allogeneic SCT for treatment of SCD or thalassemia
Patients must have one partially HLA-matched CBUs
Adequate Karnofsky Performance score or Lansky Play-Performance scale
Sufficient physiological reserves
Signed written informed consent
You CAN'T join if...
Prior allogeneic HSCT
Evidence of HIV infection or HIV positive serology
Evidence of active Hepatitis B, Hepatitis C or EBV as determined by serology or PCR
Active or uncontrolled infection
Pregnancy or lactation
UCSF Benioff Children's Hospitalaccepting new patients Oakland, California, United States
Children's Nationalaccepting new patients Washington, D.C., District of Columbia, United States
Hôpital Robert Debréaccepting new patients Paris, France